Hoechst-Roussel Pharmaceuticals, Inc: RU 486 Case Analysis
The following is a case analysis on the Hoechst-Roussel Pharmaceuticals, Inc and their product, RU 486. In this analysis, issues and concerns from shareholders and business risks with developing this new drug will be examined. Furthermore, this paper will concentrate on business opportunities with the development and marketing of the product and then focus on the cost/benefit analysis that should lead to a logical business recommendation. Finally, this paper will conclude with a description of the decision making approach. Let us begin with the general background of the company, the product and the industry.